Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

Core Viewpoint - BioPorto A/S has successfully completed a private placement of 25,000,000 new shares, raising gross proceeds of DKK 33.5 million to support its strategic initiatives and growth plans [1][2][3]. Group 1: Private Placement Details - The private placement involved 25,000,000 new shares with an aggregate subscription price of DKK 33,505,000, which is expected to be paid by April 25, 2025 [3]. - The new shares will be registered and are anticipated to be listed on Nasdaq Copenhagen A/S by April 30, 2025 [3]. Group 2: Company Strategy and Future Plans - The CEO of BioPorto expressed satisfaction with the strong commitments from existing and new investors, highlighting the importance of this support for the company's strategic direction and growth [2]. - The funds raised will be utilized to finance new clinical trials aimed at obtaining FDA clearance for the ProNephro AKI™ NGAL test for adult use in the United States, as well as to enhance the commercial platform [2]. Group 3: Company Overview and Product Focus - BioPorto specializes in in vitro diagnostics, focusing on early detection of Acute Kidney Injury (AKI) through actionable biomarkers [5][6]. - The company's flagship products utilize the NGAL biomarker to assist in the risk assessment and diagnosis of AKI, enabling quicker identification and intervention for at-risk patients [6].